Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
18.24 SEK | +6.05% | +10.28% | +17.98% |
04-17 | Orexo Expands, Extends US Patent for Nasal Anaphylaxis Treatment | MT |
04-17 | Orexo Extends Patent Protection for Its Nasal Epinephrine Powder Product OX640 in the US | CI |
Turnover - Change in analysts' estimates
Earnings Per Share (EPS) - Change in analysts' estimates
EBIT - Change in analysts' estimates
Cash or Net Debt - Change in analysts' estimates
Turnover
Earnings Per Share (EPS)
EBIT
Cash or Net Debt
- Stock Market
- Equities
- ORX Stock
- Revisions Orexo AB